ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

First participant enrolled in randomized control trial designed to demonstrate safety and efficacy of Insulet’s fully closed-loop automated insulin delivery system versus standard therapy Unique ...

Diabetes management software company Glooko will add its first two continuous glucose monitor and pump integrations into its offering: Dexcom's G4 CGM and Insulet's OmniPod Insulin Management System.

The US FDA has cleared the first updates to the algorithm of the Omnipod 5 automated insulin delivery (AID) system (Insulet Corporation) since its launch in 2022. Omnipod 5, the only tubing-free pump ...

STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types EVOLUTION 3 feasibility study demonstrates improved time in range using ...